APNHY:OTC-Aspen Pharmacare Holdings Limited (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | OTC

Last Closing Price

USD 9.60

Change

0.00 (0.00)%

Market Cap

USD 4.30B

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty, branded, and generic pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general anaesthetics and muscle relaxants under the Anaesthetics brand; cytotoxic medicines under the Regional brand; and injectable anticoagulants with a focus on low molecular weight heparins, Xa inhibitors, and heparin derivatives under the Thrombosis brand. It is also involved in the contract and supply of chemical and biochemical active pharmaceutical ingredients and finished dose form pharmaceuticals for third parties. The company offers products in the form of oral solid dose, injectables, liquids, semi-solids, steriles, biologicals, and active pharmaceutical ingredients. Aspen Pharmacare Holdings Limited was founded in 1850 and is headquartered in Durban, South Africa.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-17 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MKKGY MERCK Kommanditgesellschaft au..

N/A

USD78.66B 34.67 18.48
MKGAF MERCK Kommanditgesellschaft au..

N/A

USD78.66B 34.26 18.48
TKPHF Takeda Pharmaceutical Company ..

N/A

USD54.22B 21.22 0.12
ESALY Eisai Co., Ltd

N/A

USD21.50B 35.99 0.11
ESALF Eisai Co., Ltd

N/A

USD21.50B 32.20 0.11
SFOSF Shanghai Fosun Pharmaceutical ..

N/A

USD18.13B 27.10 3.61
SGIOF Shionogi & Co., Ltd

N/A

USD17.10B 16.95 0.08
SGIOY Shionogi & Co., Ltd

N/A

USD17.10B 2.09 0.08
TEVJF Teva Pharmaceutical Industries..

N/A

USD12.56B 900.00 16.02
MTZPY Mitsubishi Tanabe Pharma Corpo..

N/A

USD10.43B 79.00 0.21

ETFs Containing APNHY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.48% 41% F 66% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.48% 41% F 66% D
Trailing 12 Months  
Capital Gain 17.07% 54% F 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.07% 53% F 56% F
Trailing 5 Years  
Capital Gain -37.86% 34% F 26% F
Dividend Return 2.83% 33% F 13% F
Total Return -35.04% 36% F 26% F
Average Annual (5 Year Horizon)  
Capital Gain -16.06% 34% F 13% F
Dividend Return 0.48% 29% F 21% F
Total Return -15.59% 34% F 13% F
Risk Return Profile  
Volatility (Standard Deviation) 32.01% 84% B 56% F
Risk Adjusted Return -48.70% 31% F 18% F
Market Capitalization 4.30B 91% A- 81% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 9.88 49% F 65% D
Price/Book Ratio 0.89 72% C- 67% D+
Price / Cash Flow Ratio 0.52 18% F 41% F
EV/EBITDA 0.74 69% D+ 68% D+
Management Effectiveness  
Return on Equity 7.47% 82% B- 66% D
Return on Invested Capital 7.48% 69% D+ 63% D
Return on Assets 4.59% 87% B+ 83% B
Debt to Equity Ratio 51.41% 21% F 36% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.87 57% F 51% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.